Bevacizumab in the treatment of metastatic colorectal cancer

Francesco Caprioni, Giuseppe Fornarini

Research output: Contribution to journalArticle

Abstract

Anglogenesis is essential for tumor growth and metastasis, and has become a useful target for novel biological agents. Vascular endothellal growth factor (VEGF) is one of the most important anglogenesis regulators. Bevacizumab is a recombinant humanized anti-VEGF monocional antibody recently approved in Europe and the USA for first- and second-line therapy (in combination with chemotherapy) for metastatic colorectal cancer. It has a proven impact on survival, as demonstrated in large Phase III clinical trials. Treatment with bevacizumab is generally well tolerated, with hypertension and arterial thromboembolic events being the main side effects. Currently, its role in the adjuvant setting, In combination with chemotherapy, is being evaluated in large Phase III clinical trials.

Original languageEnglish
Pages (from-to)141-148
Number of pages8
JournalFuture Oncology
Volume3
Issue number2
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Phase III Clinical Trials
Combination Drug Therapy
Blood Vessels
Colorectal Neoplasms
Intercellular Signaling Peptides and Proteins
Biological Factors
Neoplasm Metastasis
Hypertension
Antibodies
Therapeutics
Growth
Neoplasms
Bevacizumab

Keywords

  • Angiogenesis
  • Bevacizumab
  • Chemotherapy
  • Colorectal carcinoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bevacizumab in the treatment of metastatic colorectal cancer. / Caprioni, Francesco; Fornarini, Giuseppe.

In: Future Oncology, Vol. 3, No. 2, 04.2007, p. 141-148.

Research output: Contribution to journalArticle

Caprioni, Francesco ; Fornarini, Giuseppe. / Bevacizumab in the treatment of metastatic colorectal cancer. In: Future Oncology. 2007 ; Vol. 3, No. 2. pp. 141-148.
@article{2e624c170c514c7ca028ab05cdf84c3b,
title = "Bevacizumab in the treatment of metastatic colorectal cancer",
abstract = "Anglogenesis is essential for tumor growth and metastasis, and has become a useful target for novel biological agents. Vascular endothellal growth factor (VEGF) is one of the most important anglogenesis regulators. Bevacizumab is a recombinant humanized anti-VEGF monocional antibody recently approved in Europe and the USA for first- and second-line therapy (in combination with chemotherapy) for metastatic colorectal cancer. It has a proven impact on survival, as demonstrated in large Phase III clinical trials. Treatment with bevacizumab is generally well tolerated, with hypertension and arterial thromboembolic events being the main side effects. Currently, its role in the adjuvant setting, In combination with chemotherapy, is being evaluated in large Phase III clinical trials.",
keywords = "Angiogenesis, Bevacizumab, Chemotherapy, Colorectal carcinoma, Survival",
author = "Francesco Caprioni and Giuseppe Fornarini",
year = "2007",
month = "4",
doi = "10.2217/14796694.3.2.141",
language = "English",
volume = "3",
pages = "141--148",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Bevacizumab in the treatment of metastatic colorectal cancer

AU - Caprioni, Francesco

AU - Fornarini, Giuseppe

PY - 2007/4

Y1 - 2007/4

N2 - Anglogenesis is essential for tumor growth and metastasis, and has become a useful target for novel biological agents. Vascular endothellal growth factor (VEGF) is one of the most important anglogenesis regulators. Bevacizumab is a recombinant humanized anti-VEGF monocional antibody recently approved in Europe and the USA for first- and second-line therapy (in combination with chemotherapy) for metastatic colorectal cancer. It has a proven impact on survival, as demonstrated in large Phase III clinical trials. Treatment with bevacizumab is generally well tolerated, with hypertension and arterial thromboembolic events being the main side effects. Currently, its role in the adjuvant setting, In combination with chemotherapy, is being evaluated in large Phase III clinical trials.

AB - Anglogenesis is essential for tumor growth and metastasis, and has become a useful target for novel biological agents. Vascular endothellal growth factor (VEGF) is one of the most important anglogenesis regulators. Bevacizumab is a recombinant humanized anti-VEGF monocional antibody recently approved in Europe and the USA for first- and second-line therapy (in combination with chemotherapy) for metastatic colorectal cancer. It has a proven impact on survival, as demonstrated in large Phase III clinical trials. Treatment with bevacizumab is generally well tolerated, with hypertension and arterial thromboembolic events being the main side effects. Currently, its role in the adjuvant setting, In combination with chemotherapy, is being evaluated in large Phase III clinical trials.

KW - Angiogenesis

KW - Bevacizumab

KW - Chemotherapy

KW - Colorectal carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=34247119151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247119151&partnerID=8YFLogxK

U2 - 10.2217/14796694.3.2.141

DO - 10.2217/14796694.3.2.141

M3 - Article

C2 - 17381413

AN - SCOPUS:34247119151

VL - 3

SP - 141

EP - 148

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 2

ER -